gatifloxacin has been researched along with levofloxacin in 221 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.81) | 18.2507 |
| 2000's | 158 (71.49) | 29.6817 |
| 2010's | 53 (23.98) | 24.3611 |
| 2020's | 6 (2.71) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Chen, S; Cui, S; McDermott, PF; Meng, J; Paulsen, I; White, DG; Zhao, S | 1 |
| Bronstein, JC; Domagala, JM; Dunham, SA; Ellsworth, EL; Gage, JW; Gracheck, SJ; Hanna, DL; Huband, MD; Joannides, ET; Liu, JY; Nguyen, DQ; Sanchez, JP; Shapiro, MA; Showalter, HD; Singh, R; Stier, MA; Tran, TP; Watson, BM | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Hashimoto, K; Hayashi, K; Ikee, Y; Nagao, Y; Nakashima, M; Sano, S; Shiro, M | 1 |
| Barth, AL; Castanheira, M; Gales, AC; Nicoletti, AG; Pereira, AS; Pignatari, AC | 1 |
| Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M | 1 |
| Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Sasaki, T; Takahata, M; Yamazaki, T | 1 |
| Clark, KP; Griffith, ME; Hawley, JS; Hospenthal, DR; Johnson, EN; Moon, JE; Murray, CK | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bonventre, EJ; Doyle, TB; Du, Q; Duncan, L; Lynch, AS; Morris, TW; Robertson, GT; Roche, ED; Yan, D | 1 |
| Jia, L; Sun, H | 1 |
| Hiramatsu, K; Hoshi, S; Kikuchi, K; Kinoshita, S; Sasaki, T; Sotozono, C | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 2 |
| Becnel Boyd, L; Morgan-Linnell, SK; Steffen, D; Zechiedrich, L | 1 |
| Becnel Boyd, L; Hamill, RJ; Horton, LB; Jimenez, JR; Maynard, MJ; Morgan-Linnell, SK; Steffen, D; Sucgang, R; Versalovic, J; Zechiedrich, L | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Barbanti, F; Barbut, F; Louie, T; Mastrantonio, P; Spigaglia, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Disratthakit, A; Doi, N | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Drlica, K; German, N; Kerns, RJ; Malik, M; Marks, KR; Schwanz, HA | 1 |
| Chai, Y; Guo, HY; Li, SJ; Liu, ML; Wang, B; Wang, JX; Zhang, YB | 1 |
| Chai, Y; Feng, LS; Guo, HY; Li, SJ; Liu, ML; Lv, K; Sun, LY; Wang, S | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Aung, TT; Beuerman, RW; Caroline, V; Chew, YS; Koh, JJ; Lakshminarayanan, R; Li, J; Lin, H; Liu, S; Pang, LM; Tan, AL; Tan, DT; Verma, C | 1 |
| Lynch, AS; Ma, Z | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Aung, TT; Beuerman, RW; Cao, D; Koh, JJ; Lakshminarayanan, R; Li, J; Lim, F; Lin, S; Liu, S; Ren, L; Tan, DT; Verma, C; Wang, L; Wang, Y; Zou, H | 1 |
| Aung, TT; Beuerman, RW; Cao, D; Koh, JJ; Lakshminarayanan, R; Lim, F; Lin, S; Liu, S; Ren, L; Sin, WLW; Tan, DTH; Wang, L; Zhou, L | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Bauernfeind, A | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Ferraro, MJ; Jorgensen, JH; Swenson, JM; Tenover, FC; Weigel, LM; Whitney, CG | 1 |
| Ambrose, PG; Grasela, DM | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ | 1 |
| Mendes, CM; Nicodemo, AC; Oplustil, CP; Sinto, S | 1 |
| Beach, ML; Jones, RN; Pfaller, MA | 1 |
| Ambrose, PG; Nicolau, DP | 1 |
| Frothingham, R | 2 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Bosso, JA; Enzweiler, KA; Friedrich, LV; Hoban, D; Wagner, D; White, RL | 1 |
| Schaeffer, AJ | 1 |
| Appelbaum, PC; Bozdogan, B; Browne, FA; Clark, C; Dewasse, BE; Jacobs, MR | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Ambrose, PG; Bhavnani, SM; Jones, RN; Rubino, CM | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yoshimori, K | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T | 1 |
| Doganay, M; Esel, D; Sumerkan, B | 1 |
| Cai, S; Kamei, T; Ogasawara, K; Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Bosso, JA; Enzweiler, KA; White, RL | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Ebisu, H; Fukuda, H; Kishii, R; Takei, M | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Gaynes, R; Johnson, TM; Killgore, G; Killum, E; Lowery, HK; Rimland, D; Tenover, FC | 1 |
| Hwang, DG | 1 |
| Acharya, B; Arakawa, S; Gotoh, A; Hinata, N; Kamidono, S; Kawabata, M; Kinoshita, S; Kofuku, T; Okada, H; Shigemura, K; Shirakawa, T | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Martinez, FJ | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Blanchard, J; Lane, LC; Levine, JM; Noecker, RJ; Rapedius, M; Snyder, RW | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Schooley, S; Stein, GE | 1 |
| Gonoi, T; Saraya, A; Seino, S; Yokokura, M | 1 |
| Greisman, J; Hoban, CJ; Hoban, DJ; Noreddin, AM; Schurek, KN; Siemens, CG; Smith, HJ; Zhanel, GG | 1 |
| Go, ES; Khurana, A; Recco, RA; Vinayek, N; Zaman, MM | 1 |
| Ba, BB; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Hoepelman, I | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Hasegawa, M; Kobayashi, I; Koyama, H; Matsuzaki, K; Sato, Y; Watabe, E | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Anon, JB | 1 |
| Hoban, DJ; Noreddin, AM; Zhanel, GG | 1 |
| Kassab, NM; Kedor-Hackmam, ER; Santoro, MI; Singh, AK | 1 |
| Graff, JM; Kesler-Diaz, A; McDonnell, PJ; Osann, KE; Reiser, BJ; Sarayba, MA; Shamie, N; Sweet, PM; Taban, M | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Burgess, DS; Frei, CR | 1 |
| Aldag, JC; Avelino, RR; Gaddamanugu, M; Graumlich, JF; Habis, S; Jamma, K; Salverson, SM | 1 |
| Kenton, I; McKinnon, PS; Mohr, JF; Okhuysen, PC; Peymann, PJ; Septimus, E | 1 |
| Garrison, MW | 1 |
| Guo, H; Li, J; Liu, Z; Nie, S; Pan, W | 1 |
| Anguita-Alonso, P; Jacofsky, DJ; Osmon, DR; Patel, R; Piper, KE; Rouse, MS | 1 |
| Dresser, L; Juurlink, DN; Kopp, A; Low, DE; Mamdani, MM; Park-Wyllie, LY; Shah, BR; Stukel, TA; Stumpo, C | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Bosso, JA; Mauldin, PD | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
| Dhalla, IA; Juurlink, DN; Kopp, A; Mamdani, MM; Rochon, PA; Simor, AE | 1 |
| Amarnath, SK; Joshi, S | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Cole, J; Mathews, S; Ryono, RA | 1 |
| Gorman, PH; Johnson, JA; Roghmann, MC; Wallin, MT | 1 |
| Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Kobayakawa, S; Shimizu, K; Tochikubo, T; Tsuji, A | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| Gidoh, M | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| De Souza, MV; Junior, IN; Lourenço, MC | 1 |
| Holland, EJ; Holland, S; McCarthy, M | 1 |
| Graves, J; Lodise, T; Lomaestro, B; Miller, C; Mohr, JF; Smith, RP | 1 |
| Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
| LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Hatou, S; Yamada, M; Yoshida, J | 1 |
| Jacob, JJ; Singh, N | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Bai, XQ; Deng, SJ; Li, L; Li, R; Liang, QF; Luo, SY; Sun, XG; Wang, ZQ | 1 |
| Scoper, SV | 1 |
| Kobayakawa, S; Tochikubo, T; Tsuchiya, Y; Tsuji, A | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Aihara, M; Eguchi, S; Minami, K; Miyanaga, M; Miyata, K; Sawaguchi, S; Shiroma, H | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Hori, Y; Inoue, T; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Sakamoto, M; Tano, Y; Yokokura, S | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Blondeau, JM; Borsos, SD; Hesje, CK | 1 |
| Choi, JA; Chung, SK | 1 |
| Asari, S; Inoue, Y; Miyai, T; Miyanaga, M; Miyata, K; Nejima, R; Ohashi, Y; Toyokawa, M | 1 |
| Chen, WJ; Huang, XD; Yao, K; Yuan, JQ; Zhang, Z | 1 |
| Gauhar, S; Iffat, W; Muhammad, IN; Shoaib, MH; Tasleem, S | 1 |
| Cai, HL; Chen, YC; Fang, PF; Gao, W; Li, HD; Liu, YP; Tan, QY; Xu, P; Zhang, F; Zhang, WY; Zhu, RH | 1 |
| Gong, L; Qiu, XD; Qu, J; Sun, XH; Xiong, QC; Yuan, ZL; Zhang, YQ | 1 |
| Kim, SJ; Toma, HS | 1 |
| Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Dalla Costa, T; de Andrade, C; Tasso, L | 1 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Bugaenko, SE; Elistratova, NA; Maliev, BM; Mozhokina, GN; Sokolova, GB; Solov'eva, IP | 1 |
| Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Fukuda, M; Hori, Y; Inatomi, T; Kinoshita, S; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Ohashi, Y; Satake, Y; Shimazaki, J; Shimomura, Y; Uno, T; Yamada, M | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Chen, ZJ; Han, L; Sun, ST; Wang, LY; Yue, J; Zhang, YQ | 1 |
| Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
| Choi, CY; Kim, HK; Kim, JM; Kim, MS | 1 |
| Bito, M; Kihira, K; Kimura, Y; Komori, M; Taogoshi, T; Tomita, T | 1 |
| Chung, JL; Kim, BY; Lee, JH; Lim, EH; Mah, FS; Seo, KY; Song, SW | 1 |
| Ohashi, Y; Suzuki, T | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Helmy, SA | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Chen, H; Ding, W; Huang, X; Ni, W; Wang, Y; Yao, K; Yu, Y; Yuan, J; Zhang, Z | 1 |
| Fukuda, M; Sasaki, H | 1 |
| Wu, L; Wu, X | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Chunqing, T; Hezhen, T; Shuying, W; Xiaoli, Z | 1 |
| Feng, J; Xu, J | 1 |
| Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS | 1 |
| Capparelli, E; Catanzaro, DG; Rodwell, TC; Seifert, M | 1 |
| Boonmars, T; Laummaunwai, P; Sanpool, O; Thongseesuksai, T; Wongwai, P | 1 |
| Aung, KJM; Decroo, T; Kuaban, C; Noeske, J; Piubello, A; Rieder, HL; Van Deun, A | 1 |
| Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA | 1 |
| Lin, Y; Miao, M; Shao, Y; Wang, B; Ye, G | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| He, Y; Li, X | 1 |
9 review(s) available for gatifloxacin and levofloxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2005 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2008 |
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary | 2019 |
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacterial; Furazolidone; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Nitrofurantoin; Norfloxacin; Novobiocin; Rifampin; Vibrio cholerae; Virulence Factors | 2022 |
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary | 2022 |
13 trial(s) available for gatifloxacin and levofloxacin
| Article | Year |
|---|---|
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcus aureus; Treatment Outcome | 2001 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cornea; Corneal Transplantation; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions | 2007 |
A comparison of fluoroquinolone penetration into human conjunctival tissue.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Changes in drug susceptibility and the quinolone-resistance determining region of Staphylococcus epidermidis after administration of fluoroquinolones.
Topics: Aged; Aged, 80 and over; Bacterial Proteins; Cataract Extraction; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Ophthalmic Solutions; Polymerase Chain Reaction; Prospective Studies; Staphylococcus epidermidis | 2009 |
[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aqueous Humor; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions | 2009 |
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
Topics: Adolescent; Adult; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Young Adult | 2010 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2012 |
Effect of gatifloxacin in the treatment of ophthalmological diseases and continuous nursing intervention.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Eye Foreign Bodies; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Young Adult | 2018 |
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis.
Topics: Adolescent; Adult; Aged; Conjunctivitis, Bacterial; Double-Blind Method; Female; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ophthalmic Solutions; Young Adult | 2018 |
199 other study(ies) available for gatifloxacin and levofloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
Topics: Animals; Anti-Infective Agents; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Gene Targeting; Genes, Bacterial; Mutation; Salmonella Infections, Animal; Salmonella typhimurium | 2007 |
3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
Topics: Anti-Bacterial Agents; Bacteria; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Methicillin Resistance; Microbial Sensitivity Tests; Quinazolinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane.
Topics: Anti-Bacterial Agents; Aza Compounds; Bridged Bicyclo Compounds; Crystallography, X-Ray; Indicators and Reagents; Magnetic Resonance Spectroscopy; Methicillin Resistance; Microbial Sensitivity Tests; Models, Molecular; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Conjugation, Genetic; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Integrons; Latin America; Molecular Sequence Data; Plasmids | 2007 |
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Injections, Intraperitoneal; Leptospira interrogans; Leptospirosis; Levofloxacin; Mesocricetus; Ofloxacin; Serotyping; Survival Analysis | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Rifamycins; RNA, Bacterial; Staphylococcus aureus; Topoisomerase II Inhibitors | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu
Topics: Administration, Topical; Anti-Bacterial Agents; Drug Administration Routes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Ophthalmic Solutions; Staphylococcus aureus | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Norfloxacin; Ofloxacin | 2009 |
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; United States | 2009 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Topics: Aza Compounds; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2009 |
Emergence of quinolone-resistant Bordetella pertussis in Japan.
Topics: Anti-Bacterial Agents; Bordetella pertussis; Child; DNA Gyrase; Fluoroquinolones; Humans; Japan; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Quinolones | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship | 2009 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
Topics: Anti-Infective Agents; Chloramphenicol; Escherichia coli; Fluoroquinolones; Levofloxacin; Ofloxacin; Oxazines; Structure-Activity Relationship | 2010 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Line; Cell Survival; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fluoroquinolones; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcus; Stereoisomerism; Structure-Activity Relationship | 2011 |
Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.
Topics: Animals; Anti-Bacterial Agents; Cell Survival; Chlorocebus aethiops; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; In Vitro Techniques; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Spectrometry, Mass, Fast Atom Bombardment; Vero Cells | 2011 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cell Membrane; Cell Survival; Drug Resistance, Bacterial; Enterobacteriaceae; Fatty Acids; Female; Fibroblasts; Gram-Negative Bacteria; Hemolysis; Humans; In Vitro Techniques; L-Lactate Dehydrogenase; Lipopeptides; Lipopolysaccharides; Male; Mice; Microbial Sensitivity Tests; Permeability; Rabbits | 2015 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.
Topics: Animals; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Staphylococcal Infections; Surface-Active Agents; Xanthones | 2017 |
Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Arginine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cell Survival; Drug Resistance, Bacterial; Fibroblasts; Flavones; Hemolysis; Humans; Keratitis; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Mimicry; Rabbits; Staphylococcus aureus; Structure-Activity Relationship | 2017 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2000 |
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Topics: Anti-Infective Agents; Ciprofloxacin; Databases, Factual; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Pseudomonas aeruginosa | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Gatifloxacin; Humans; Lactams; Latin America; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Regional Medical Programs; Urinary Tract Infections | 2001 |
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Ofloxacin; Predictive Value of Tests; Streptococcus pneumoniae | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2002 |
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Penicillins; Thienamycins | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Topics: Anti-Infective Agents; Area Under Curve; Drug Resistance, Bacterial; Epidemiologic Methods; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2003 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprofloxacin; Dosage Forms; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Macrolides; Ofloxacin; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors; Urinary Tract Infections | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Levofloxacin; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2003 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin G; Penicillins; Turkey | 2003 |
Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Cell Line; Epithelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Macrophages; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli | 2003 |
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Formularies, Hospital as Topic; Gatifloxacin; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Area Under Curve; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Theoretical; Ofloxacin; Streptococcus pneumoniae | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.
Topics: Case-Control Studies; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Disease Outbreaks; Drug Resistance, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Levofloxacin; Long-Term Care; Microbial Sensitivity Tests; Ofloxacin | 2004 |
Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gonorrhea; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Instillation, Drug; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Reference Standards | 2004 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Levofloxacin; Lung; Mice; Mice, Inbred CBA; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Survival Rate | 2004 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Cells, Cultured; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Islets of Langerhans; Levofloxacin; Mice; Ofloxacin; Patch-Clamp Techniques; Potassium Channels; Quinolones | 2004 |
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2004 |
The incidence of Clostridium difficile-associated and non-C. difficile-associated diarrhea after use of gatifloxacin and levofloxacin in an acute-care facility.
Topics: Clostridioides difficile; Clostridium Infections; Diarrhea; Emergency Medical Services; Fluoroquinolones; Gatifloxacin; Humans; Incidence; Levofloxacin; Ofloxacin | 2004 |
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching.
Topics: Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Moxifloxacin; Ofloxacin; Quality Control; Quinolines; Reference Standards; Reproducibility of Results | 2004 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
[Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Quinolones | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Levofloxacin; Middle Aged; Monte Carlo Method; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Streptococcus pneumoniae | 2005 |
Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibiotics in pharmaceutical preparations by high-performance liquid chromatography.
Topics: Anti-Bacterial Agents; Calibration; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Ethylamines; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Models, Chemical; Models, Statistical; Ofloxacin; Pefloxacin; Pharmaceutical Preparations; Quinolones; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets; Temperature; Time Factors | 2006 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantation; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Rabbits | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Topics: Anti-Bacterial Agents; Area Under Curve; Ceftriaxone; Computer Simulation; Databases, Factual; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intravenous; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Ofloxacin; Streptococcus pneumoniae | 2005 |
Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Case-Control Studies; Female; Fluoroquinolones; Gatifloxacin; Humans; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Risk Factors | 2005 |
A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Ceftriaxone; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Product Surveillance, Postmarketing; Retrospective Studies | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; DNA, Bacterial; Evaluation Studies as Topic; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2006 |
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.
Topics: 1-Octanol; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cornea; Drug Carriers; Enoxacin; Ethylene Glycols; Eye; Fluoroquinolones; Gatifloxacin; In Vitro Techniques; Irritants; Levofloxacin; Ofloxacin; Oxaprozin; Permeability; Propionates; Rabbits; Ribavirin; Water | 2006 |
Comparative study of antimicrobial release kinetics from polymethylmethacrylate.
Topics: Acetamides; Anti-Bacterial Agents; Area Under Curve; Cefazolin; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Polymethyl Methacrylate; Rifampin | 2006 |
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Diabetes Complications; Female; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Macrolides; Male; Ofloxacin; Ontario; Risk | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluoroquinolones; Formularies as Topic; Gatifloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Methicillin; Methicillin Resistance; Ofloxacin; Pseudomonas aeruginosa; Regression Analysis; Retrospective Studies; Staphylococcus aureus | 2006 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A; Salmonella typhi | 2007 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.
Topics: Aged; Anticoagulants; Databases as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; International Normalized Ratio; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; United States; Warfarin | 2006 |
Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction.
Topics: Anti-Bacterial Agents; Carrier State; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Negative Aerobic Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Perineum; Prevalence; Prospective Studies; Spinal Cord Diseases; Urinary Catheterization; Urinary Incontinence; Urinary Tract Infections | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Biofilm formation on hydrophilic intraocular lens material.
Topics: Acrylic Resins; Animals; Bacterial Adhesion; Biofilms; Colony Count, Microbial; Drug Carriers; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Hydrogel, Polyethylene Glycol Dimethacrylate; Lenses, Intraocular; Levofloxacin; Microscopy, Electron, Scanning; Ofloxacin; Polymethyl Methacrylate; Rabbits; Staphylococcus epidermidis | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil.
Topics: AIDS-Related Opportunistic Infections; Brazil; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis | 2007 |
Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; Hyperglycemia; Hypoglycemia; Kidney Diseases; Levofloxacin; Logistic Models; Male; Medication Errors; Ofloxacin; Retrospective Studies | 2007 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |
Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Creatinine; Diabetes Complications; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Medical Records; Middle Aged; Multivariate Analysis; Ofloxacin; Prevalence; Retrospective Studies; Rhode Island; Risk Factors | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Child; Conjunctiva; Drug Resistance, Microbial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2008 |
Levofloxacin and hypoglycemia.
Topics: Clinical Competence; Fluoroquinolones; Gatifloxacin; Health Services Research; Hospitals, University; Humans; Hypoglycemia; Levofloxacin; Ofloxacin; Surveys and Questionnaires | 2008 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
[Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Eye; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2008 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Colony Count, Microbial; Drug Delivery Systems; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Lens Implantation, Intraocular; Lenses, Intraocular; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Postoperative Complications; Rabbits | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Preoperative Care; Quinolines | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2009 |
Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability.
Topics: Animals; Anterior Chamber; Anti-Infective Agents; Cell Survival; Endophthalmitis; Endothelium, Corneal; Female; Fluoroquinolones; Gatifloxacin; Injections; Levofloxacin; Male; Microscopy, Electron, Scanning; Ofloxacin; Rabbits | 2009 |
Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2010 |
Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Animals; Antibiotics, Antitubercular; Brain Chemistry; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gatifloxacin; Intestine, Small; Isoniazid; Kidney; Least-Squares Analysis; Levofloxacin; Liver; Lung; Male; Methanol; Mice; Ofloxacin; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolerance; Fluoroquinolones; Gatifloxacin; Isoxazoles; Levofloxacin; Mice; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Rifabutin; Tuberculosis | 2011 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; Female; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Keratitis; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
[The changes of ocular bacterial isolates and in vitro antimicrobial susceptibility in the past six years].
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Eye; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Retrospective Studies; Staphylococcus epidermidis; Tobramycin | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops.
Topics: Anti-Bacterial Agents; Aspergillus niger; Bacteria; Bacteriological Techniques; Benzalkonium Compounds; Candida albicans; Colony Count, Microbial; Drug Contamination; Eye Diseases; Female; Fluoroquinolones; Fungi; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prospective Studies; Pseudomonas aeruginosa; Staphylococcus aureus | 2013 |
The mechanisms of insulin secretion and calcium signaling in pancreatic β-cells exposed to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Calcium Signaling; Cell Line; Cricetinae; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Insulin-Secreting Cells; Levofloxacin; Ofloxacin; Tolbutamide | 2013 |
Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Biological Availability; Chromatography, High Pressure Liquid; Conjunctiva; Cornea; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Tissue Distribution; Vitreous Body | 2013 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas; Quinolines; Staphylococcus; Streptococcus; Tobramycin | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aqueous Humor; Cataract; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ophthalmic Solutions | 2015 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Rabbits; Time Factors; Wound Healing | 2015 |
Molecularly imprinted polymers for the solid-phase extraction of four fluoroquilones from milk and lake water samples.
Topics: Animals; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Gatifloxacin; Lakes; Levofloxacin; Milk; Molecular Imprinting; Polymethyl Methacrylate; Solid Phase Extraction; Water Pollutants, Chemical | 2015 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide | 2019 |
Evaluating the in vitro efficacy of gatifloxacin, levofloxacin and gentamicin against Acanthamoeba cysts.
Topics: Acanthamoeba; Amebiasis; Animals; Eye Infections, Parasitic; Gatifloxacin; Gentamicins; Humans; Levofloxacin; Ophthalmic Solutions | 2020 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug Administration Schedule; Female; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Niger; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomycin; Furazolidone; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ornidazole; Rifampin; Tinidazole | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |